Maraviroc

CCR5 Co-receptor Antagonist — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Maraviroc is an ofp drug in the CCR5 Co-receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Chemokine Co-receptor 5 Antagonists. DrugCentral lists 5 molecular targets, including CCR5, Ccr5 and CCR5. Recorded indications include CCR5 Tropic Drug Resistant HIV Infection.

• Approval status: ofp (first approved 2007 by the FDA).
• Drug class: CCR5 Co-receptor Antagonist.
• Mechanism of action: Chemokine Co-receptor 5 Antagonists.
• Molecular targets: CCR5, Ccr5, CCR5 and KCNH2 (5 listed in DrugCentral).
• Indications: CCR5 Tropic Drug Resistant HIV Infection.
• ATC code: J05AX09 (Other antivirals).
• Molecular formula: C29H41F2N5O; molecular weight 513.68 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• CCR5 Tropic Drug Resistant HIV Infection

Contraindications (14)

• Acute nephropathy
• Breastfeeding (mother)
• Cardiovascular event risk
• Chronic renal failure syndrome
• Chronic type B viral hepatitis
• Disease of liver
• Disorder of coronary artery
• Drug-induced hepatitis
• Infectious disease
• Kidney disease
• Myocardial infarction
• Myocardial ischemia
• Orthostatic hypotension
• Viral hepatitis C

Mechanism & targets

• Mechanism of action (MoA): Chemokine Co-receptor 5 Antagonists
• Established pharmacologic class: CCR5 Co-receptor Antagonist

Molecular targets (5)

Target	Gene	Action	Activity
C-C chemokine receptor type 5	CCR5	unknown	Ki 9.62
C-C chemokine receptor type 5	Ccr5	unknown	IC50 8.28
C-C chemokine receptor type 5	CCR5	antagonist	Kd 7.60
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.11
Multidrug and toxin extrusion protein 1	SLC47A1	unknown	IC50 4.76

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-08-06	FDA	—	VIIV HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
J05AX09	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CCR5
• Swissmedic label: CYP3A5 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Virologic failure	712.2
Viral mutation identified	631.1
Pathogen resistance	476.9
Drug resistance	180.3
Immune reconstitution inflammatory syndrome	127.8
Blood HIV RNA increased	118.7
Treatment noncompliance	117.2
Viral load increased	111.3
Abortion spontaneous	85.6
Progressive multifocal leukoencephalopathy	81.1
Lipodystrophy acquired	80.4
CSF HIV escape syndrome	74.9

Chemical structure

• Molecular formula: C₂₉H₄₁F₂N₅O
• Molecular weight: 513.68 g/mol
• CAS number: 376348-65-1
• InChIKey: GSNHKUDZZFZSJB-QUMGSSFMSA-N
• PubChem CID: 3002977

CC(C)C1=NN=C(C)N1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Maraviroc used for?

DrugCentral lists the following indications for Maraviroc: CCR5 Tropic Drug Resistant HIV Infection.

How does Maraviroc work?

Maraviroc is classified as Chemokine Co-receptor 5 Antagonists; its molecular targets in DrugCentral include CCR5, Ccr5, CCR5 (antagonist) and KCNH2.

When was Maraviroc first approved?

Maraviroc was first approved by the FDA in 2007.

What drug class does Maraviroc belong to?

Maraviroc is in the CCR5 Co-receptor Antagonist class.

What is the chemical formula of Maraviroc?

Maraviroc has the molecular formula C29H41F2N5O and a molecular weight of 513.68 g/mol.

Sources

• DrugCentral drug card 1635 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL256907 — compound record and bioactivity
• PubChem CID 3002977 — chemical identifiers
• DrugBank DB04835 — drug record
• FDA UNII MD6P741W8A — substance identity
• DailyMed: FDA labels for Maraviroc — current prescribing information (label search)
• UniProt P51681 (CCR5) — target protein
• UniProt Q12809 (KCNH2) — target protein
• UniProt Q96FL8 (SLC47A1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.